India, June 4 -- Anupam Rasayan's proposed acquisition of Bliss GVS Pharma appears to be a strategically significant move that could strengthen the company's long-term growth trajectory. Management believes the transaction offers substantial portfolio expansion opportunities while providing access to the pharmaceutical formulations segment, thereby reducing dependence on its traditional specialty chemicals business.

Anupam Rasayan India Limited has a total market capitalization of approximately Rs. 15,189.64 crore. The company's shares were trading at Rs. 1334.20 apiece on the National Stock Exchange, up by 0.53 percent; the stock has declined around 2.47 percent over the last five sessions, while it has gone down about 1.02 percent in t...